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INTRODUCTION AND LITERATURE REVIEW 
 
Cardiovascular disease is a major cause of morbidity and mortality worldwide, especially in  
 
industrialised societies. With South Africa undergoing rapid urbanisation in the post-apartheid  
 
era, adverse cardiovascular events, including acute myocardial infarction, are becoming more  
 
prevalent.(1,2) 
 
While prevention of disease is the ideal, morbidity and mortality in individuals with acute  
 
myocardial infarction can be reduced with early administration of fibrinolytic therapy.  The  
 
major benefit of early finbrinolysis lies in resolving the patency of the affected coronary artery.  
 
This reduces the infarct size of the myocardium. A delay in thrombolytic treatment by half an  
 
hour can reduce life expectancy by approximately one year in patients with acute myocardial  
 
infarction.(3,4) 
 
The American Heart Association and American College of Cardiologists (AHA/ACC) guidelines  
 
recommend a door to needle time of 30 minutes for administration of fibrinolytics in patients  
 
with acute ST Segment Elevation Myocardial Infarction (STEMI).(5) This time period is  
 
considered as the gold standard for thrombolyisis and compliance with this is regarded as a  
 
marker of quality of care.(6) 
 
The majority of patients with acute myocardial infarction in the Cape Metropole, are initially  
 
seen in the emergency centres (EC).  Emergency centres are often overcrowded and  
 
understaffed, and despite good triage, delays in managing patients with myocardial infarction  
 
can occur.  
 
Audits performed internationally; show that most hospitals fail to achieve a door to needle time  
 
in about half of their patients.(6,7) 
 
Several factors have been identified as contributing to these delays. These include: delays in  
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obtaining or interpreting ECGs, obtaining a cardiology consult before initiating thrombolysis,  
 
thrombolysis being given in the ICU/CCU rather than the Emergency Centre, the time of day that  
 
patient presented to hospital and prehospital factors eg. inappropriate prehospital diagnosis  
 
and incorrect referral.(7,8,9) 
 
 
 
 
AIM OF STUDY 
 
The aim of this study is to determine the current door to needle time for administration of  
 
fibrinolytics in acute myocardial infarction in Emergency Centres in the Cape Metropole. This  
 
study will also aim to identify the factors contributing to the delay. 
 
 
STUDY DESIGN 
 
A RETROSPECTIVE audit will be conducted of all patients who received fibrinolytics for acute  
 
myocardial infarction in the emergency units of four hospitals in the Western Cape Metropole. 
 
Data will be collected from Groote Schuur Hospital, GF Jooste Hospital, New Somerset Hospital  
 
and Victoria Hospital. The clinical records of all patients who received fibrinolytic therapy for  
 
acute myocardial infarction in these emergency centres will be reviewed. These patients will be  
 
identified by the Emergency Centre Register. 
 
Inclusion Criteria: 
 
All patients with Acute ST Segment elevation or new onset LBBB on ECG meeting ACC/AHA  
 
criteria for fibrinolysis who received fibrinolytics in the emergency centre from 1 January 2008  
 
to 31 July 2010. 
 
 
Exclusion Criteria 
 
• Patients who received prehospital fibrinolytics.   
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• Patients receiving fibrinolytics for conditions other than acute myocardial infarction. 
 
From the case notes the following data will be collated and analysed: 
 
• Time of presentation to hospital (taken from ambulance record/admission chart) 
 
• Time taken to triage 
 
• Time to ECG  
 
• Time from ECG and to start of thrombolysis. This will include interpreting the ECG,  
 
        obtaining consent for administration of fibrinolytics, obtaining IV access, and preparing  
 
        the fibrinolytics for administration. Streptokinase is the fibrinolytic available in the  
 
        public sector hospitals for treatment of ST elevation myocardial infarction. It needs to  
 
        be reconstituted and given as an infusion. 
 
• Total door-to-needle time will therefore be from presentation to lysis. 
 
• Factors that may contribute to delay in receiving thrombolytics in our setting include: 
 
- private transport vs ambulance 
 
- patient demographics, language barrier 
 
- time of onset of pain 
 
- time of  day that patient presents to Emergency Department 
 
- anatomical localization of infarct 
 
- level of experience of physician 
 
- atypical presentations 
 
REFER TO ANNEXURE A 
 
Estimated sample size is 600 
 
All data will be collated on an EXCEL spread-sheet. Simple descriptive statistics will be used to  
 
describe the median time-to-triage, time-to -ECG and door-to-needle times for each Emergency  
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Centre.  
 
Subgroup analyses will be performed for different sexes, age groups, anatomical localization of  
 
MI, transport types and physician experience. 
 
 
 
ETHICS 
 
Data will be collected from patient records by a single researcher. Permission will be obtained  
 
from the relevant hospitals to access these records. Patients will only be identified by hospital  
 
numbers. All data will be kept on a password protected database. 
 
 
FUNDING 
No funding required. 
 
 
 
TIMELINE 
 
This study will commence once Research Committee and Ethical Approval has been obtained. It  
 
is aimed to complete this dissertation for submission in August 2011. 
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ANNEXURE  A 
 
DATA COLLECTION SHEET 
 
Patient Number:  _________________________ 
DEMOGRAPHICS: 
 Age: _____            Sex: ______             
 
AMBULANCE:  Y / N      
FORWARD ALERT BY PREHOSPITAL STAFF:  Y/N                 PREHOSPITAL ECG:  Y/N 
 
LEVEL OF EXPERIENCE OF TREATING PHYSICIAN:  INTERN, CSO, MO, REGISTRAR, CONSULTANT 
 
CLINICAL:     
 Time of Onset of Pain:  ________  Time of Day:  W/H, A/H 
 Anatomical localization: _________ 
 Typical Symptoms        Y / N 
 If no describe:  _________________________________ 
 
 
 DURATION COMMENT 
 TIME OF ARRIVAL   
TIME FROM ARRIVAL TO 
TRIAGE 
 
  
TIME FROM TRIAGE TO ECG               
TIME FROM ECG TO ACTUAL 
ADMINISTRATION OF 
FIBRINOLYTIC 
  
TOTAL DOOR TO NEEDLE 
TIME 
  
 
KEY:   Y – YES 
           N – NO  
           CSO – COMMUNITY  SERVICE OFFICER 
           MO – MEDICAL OFFICER 
           W/H – WORKING HOURS ( 08:00 – 17:00) 
           A/H – AFTER HOURS ( 17:01 – 07:59) 
 
COMMENT: IDENTIFY DELAY IN DOOR TO NEEDLE TIME IF ANY 
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LITERATURE REVIEW 
 
 
AIM: 
 
The aim of this literature review is to: 
 
• Determine the global impact of Ischaemic Heart Disease (IHD). 
 
• Review the epidemiology of IHD in the Western Cape. 
 
• Review the current management of ST Elevation Myocardial Infarction (STEMI). 
 
• Identify local research on door to needle time for the administration of 
 
              thrombolytics for Acute Myocardial Infarction (AMI)  in emergency centres.  
 
• Identify factors affecting the door to needle time internationally. 
 
• Identify quality improvement strategies to optimise the management of STEMI patients  
 
               in Cape Town. 
 
 
LITERATURE SEARCH STRATEGY: 
 
The database of Medline, Pre-Medline and Embase on the OVID platform and Google Scholar   
 
were searched. Search words included, ST elevation myocardial infarction, thrombolytics,  
 
fibrinolysis, door to needle times, delay in door to needle time, quality analysis. 714 articles  
 
were identified from the above databases.  In addition unpublished articles and web- 
 
sites (Biomed Central, Greynet) were sourced and 44 articles were identified, of these. A review  
 
of the references of these articles yielded a further 17 articles. A final total of 80 articles were  
 
selected on the basis of validity and relevance to this study. 
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LITERATURE APPRAISAL 
 
Introduction: 
 
Ischaemic heart disease (IHD) is a major cause of morbidity and mortality worldwide, with a high  
 
prevalence noted in industrialised societies.(1)  In the United States approximately 732 000 of  
 
the annual 6 million patients  with chest pain, seen  in  Emergency Centres (EC), are admitted  
 
with Acute Myocardial Infarction (AMI).(2)  Mortality statistics show that South Africa is  
 
currently experiencing a quadruple burden of disease, namely infectious conditions  such as  
 
tuberculosis; chronic diseases (diabetes, hypertension, cardiovascular diseases); HIV/AIDS; and  
 
mortality and morbidity from  injuries resulting from interpersonal violence.(3)  
 
 
With South Africa undergoing rapid urbanisation in the post-apartheid era, risk factors for  
 
IHD and adverse cardiovascular events, including AMI are becoming more prevalent.(4-6)  
 
In South Africa, data collected on disease profiles is based on findings from death  
 
notification forms received from the Department of Home Affairs.(7) This is the basis of   
 
mortality statistics from a particular disease. Although these are important and can be  
 
used to implement interventions, there are certain limitations to these statistics as recognised  
 
by Stats SA.(7) These include errors in filling out death notification forms, under registration of  
 
deaths and filling in the incorrect cause of death. In addition historical factors have influenced 
 
 epidemiological studies in South Africa. Stats SA only began collecting data representative  
 
of all population groups from 1997 onwards.(7,8) Cause of death was classified by the ICD 10 
 
 coding system. Deaths from IHD consistently appeared amongst the top 10 causes of natural  
 
deaths in the country. Sub group analysis showed that acute myocardial infarctions accounted  
 
for more than 70 % of deaths in the IHD group (2003/2004 Statistics).(8) 
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A higher mortality from IHD was seen in males and a higher overall incidence was seen in the  
 
White and Indian population compared to the Black and Coloured population.(7,8) Recently  
 
released 2008 mortality  statistics show that IHD was the number one cause of natural death in  
 
Whites, while it was the second and fourth leading cause of death in Asian/Indians and  
 
Coloureds respectively.(9) There is a paucity of data  on the prevalence of AMI  and number of  
 
AMIs admitted to our ECs.  Data extrapolated from a recent audit of clinical presentations and  
 
procedures in  ECs of three Western Cape hospitals, revealed that acute coronary syndromes  
 
and chest pain made up 1.2% and 2.9% of all clinical presentations respectively.(10)  
 
Electrocardiograms (ECGs) made up 9.2% , and thrombolysis accounted for 1.2% of procedures  
 
performed in the ECs collectively.(10) 
 
 The treatment of patients is usually initiated in the EC, thus making the functioning of an EC a   
 
critical component in the initiation of management of patients with AMI. The type, quality and  
 
timeliness of care AMI patients receive can have a significant impact on patient mortality and  
 
morbidity.(11-13)  
  
 
 Primary prevention of IHD, through early screening and detection of risk factors, lifestyle  
 
modification and aggressive treatment of hypertension, diabetes and hypercholesterolaemia is  
 
the ideal.(6, 14)  For those already with established disease and presenting with AMI,  mortality  
 
and morbidity can be significantly reduced with early reperfusion interventions.(15)  
 
 In South Africa two strategies may be employed to emergently manage patients presenting  
 
with acute ST Elevation Myocardial Infarction (STEMI) –  fibrinolytic drug therapy, which can be  
 
initiated in the EC, or primary Percutaneous Coronary Intervention (PCI). Regardless of the  
 
strategy chosen, the adage that time is muscle should be adhered to for patients presenting  
 
with AMI.(15) 
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The Global Impact of Ischaemic Heart Disease: 
 
The 2004 World Health Organisation (WHO) Global Burden of Disease survey, listed IHD as the  
 
leading cause of death globally.(16) Mortality from IHD was highest in the high income  
 
countries, but also featured high on the mortality  list in the middle and low income  
 
countries.(16) In the United States coronary heart disease was the single leading cause of   
 
death.(17) IHD also accounted for a high incidence of hospital admissions in Europe.(18)  The  
 
projected trends in global  mortality by 2030, as determined by WHO, further predicted IHD as a  
 
leading cause of mortality in 2030.(16) The years of life lost due to premature mortality and  
 
disability could have a significant impact on the worlds economy. 
 
 
The Burden of Ischaemic Heart Disease in the Western Cape:   
 
In the Western Cape, cardiovascular disease was the leading cause of mortality in both males  
 
and females, accounting for 25% of all deaths in the year 2000.(3)  Ischaemic heart disease   
 
was the single leading cause of mortality in this category and accounted for 12% of all deaths in  
 
2000.(3)  Data from Stats SA consistently places IHD in the top five natural causes of mortality in  
 
the Western Cape.(9)  (see Table 1) 
 
Table 1: Top 5 Natural Causes of Death, Western Cape (9) 
 
 
CAUSE OF DEATH 
(BOTH SEXES) 
% CAUSE OF 
DEATH 
(MALE) 
% CAUSE OF DEATH 
(FEMALES) 
% 
Tuberculosis 9.7 Tuberculosis 10.5 Tuberculosis  8.7 
Ischaemic Heart 
Disease 
5.9 Ischaemic Heart 
Disease 
6.2 Diabetes Mellitus 7.8 
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Diabetes Mellitus 5.8 Chronic Lung 
Disease 
4.6 Cerebrovascular 
Disease 
6.4 
Cerebrovascular 
Disease 
5.6 Diabetes 
Mellitus 
4.2 Ischaemic Heart 
Disease 
5.6 
Human 
Immunodeficiency 
Virus (HIV) 
4.3 Cerebrovascular 
Disease 
4 Human 
Immunodeficiency 
Virus (HIV) 
5.1 
 
 
 
Mortality from IHD was found to be the highest in the City of Cape Town, Overberg, Eden and  
 
West Coast district municipalities of the Western Cape. (9)  The hospitals chosen in this study  
 
service most of these drainage areas. 
 
 
Men had a higher mortality from IHD than women in keeping with national statistics. (3, 9)  
 
Women however died more often from diseases that are risk factors or predictors for IHD  
 
(diabetes, hypertension, stroke).(3) 
 
With age stratifying cause of mortality, IHD was the leading cause of mortality in males over 60 
 
 years (20.4%),  while it was second only to tuberculosis in males aged 45-59. It accounted for  
 
 
12.8% of deaths in this age group. In the female population similar trends were noted with  
 
stroke being the leading cause of death between ages 45-59 years. Notably IHD featured as the  
 
6th leading cause of death in males less than 44 years (2.3%).(3) 
 
 
Hence, IHD and its risk factors account for significant mortality in the Western Cape. Compared  
 
to the rest of the country, non communicable/chronic diseases such as diabetes, hypertension  
 
and cardiovascular diseases resulted in a higher number of deaths in the Western Cape (58% vs.  
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38%). This was attributed to the population of the Western Cape being older than the national  
 
population, hence the higher mortality from chronic diseases.(3) IHD and other non  
 
communicable diseases are traditionally more prevalent in western affluent societies.  
 
However studies done by the Medical Research Council (MRC) in collaboration with the  
 
School of Public Health (University of Western Cape), showed higher mortality rates from non  
 
communicable diseases in the poorer districts of Cape Town compared to the more affluent  
 
areas (19).  The INTERHEART Africa Study with approximately 80% of participants from South  
 
Africa studied the impact of modifiable cardiovascular risk factors on myocardial infarction in  
 
Sub-Saharan Africa. In the Coloured-African group which was recruited from hospitals serving a  
 
low socioeconomic population, revealed that this ethnic group adopted “a hazardous,  
 
westernised lifestyle” with high rates of smoking and obesity.(20) Steyn et al in a community  
 
based cross sectional study in the Cape Peninsula, also reinforced the high prevalence of  
 
hypertension, smoking, and hyperlipidaemia in subjects.(21) 
 
 This highlights the fact that there is a high prevalence of risk factors for IHD especially  
 
myocardial infarction present across all socioeconomic groups in the Western Cape  
 
population.(21,22) No specific current data could be found for hospital presentations with acute  
 
STEMI in the Western Cape. 
 
 
The Impact of Cardiovascular Disease on the Economy: 
 
In determining the impact of disease on society and the economy, the 2000 Burden of Disease  
 
Study determined the years of life lost from death from a particular disease. The impact of the  
 
cardiovascular group on years of life lost was not considered as dramatic by the authors. (22)  
 
The reason being that the elderly (age > 60 yrs) were the most affected. However it should be  
 
 
 
17 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
                                                
noted that the average working age of the South African population, including that in the  
 
Western Cape has increased. This could mean that more people of working age will be affected  
 
by cardiovascular disease, having a negative impact on the countries economy.(22)  
 
 Statistics from the Department of Health records of 2002 indicate that the direct health care  
 
costs of managing  patients with cardiovascular diseases are much higher compared to other  
 
conditions. Costs per bed per day were six times higher than those of the average patients  
 
admitted in a tertiary facility, and almost ten times higher in a regional/district hospital.(22) 
 
In response to the findings from the 2000 Burden of Disease survey, the Western Cape has  
 
initiated a task force to develop appropriate interventions to address the current pathology  
 
present.(22) 
 
 
Optimal Management of STEMI: 
 
Reperfusion therapy remains the main form of treatment for eligible STEMI patients. Various  
 
trials and meta-analysis has shown that early PCI has more advantages than fibrinolysis. PCI  
 
reduces mortality from re-infarction and the need for Coronary Artery Bypass Grafting (CABG)  
 
more than fibrinolysis.(23- 28) However access to PCI is often limited.  
 
Access to PCI in the Western Cape public sector is limited to two tertiary hospitals, making  
 
fibrinolysis the most accessible reperfusion strategy available to most people. 
 
 
The major benefit of early administration of fibrinolysis lies in resolving the patency of the  
 
affected coronary artery. This reduces the infarct size of the myocardium and improves left  
 
ventricular function. There is also conclusive evidence that fibrinolytics reduce mortality in  
 
patients with STEMI if given within 6-12hrs after onset of symptoms.(29 -34) Meta analysis of  
 
all randomised fibrinolytic trials, with more than 1000 patients, done by the Fibrinolytic Therapy 
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 Trialist group showed that a shorter time from onset of symptoms to fibrinolysis resulted in a  
 
greater mortality benefit.  The greatest mortality benefit was seen in patients fibrinolysed within  
 
3 hours of presentation following STEMI, especially in the first hour.(35,36)  
 
Statistical improvement in mortality was seen up to 12 hours post symptom onset. There was an  
 
absolute mortality benefit of 39 lives saved per 1000 patients if treated within one hour post  
 
onset of symptoms; 30 lives/1000 if treated within 2 -3 hours and 21/1000 if treated between 7- 
 
12 hours. There was an absolute benefit reduction of 1.6 lives/1000 for every hour of 
 
delay.(37,38) Early reperfusion also resulted in lower 30 day mortality. Data analysed  
 
retrospectively from The Myocardial Infarct Triage and Intervention (MITI)  trial showed a 7 fold  
 
reduction of 30 day mortality in patients treated within 70 minutes of symptoms compared to  
 
those treated later (1.2% vs 7%).(37) The GREAT trial also confirmed  that a delay in fibrinolytic  
 
treatment by half an hour can reduce life expectancy by pproximately 1 year in patients with  
 
STEMI.(37, 39-42/32) Hence maximal benefit in re-establishing  coronary vessel patency and  
 
reducing morbidity and mortality in STEMI patients is achieved if patients present early to a  
 
facility with reperfusion capability.  
 
 
The Administration of Fibrinolytics : 
 
The defined American Heart Association/American College of Cardiology (AHA/ACC) criteria for  
 
fibrinolysis are: 
 
• chest pain duration of less than 12 hours 
 
•  ECG showing ST elevation of 2mm or more in chest leads and 1 mm or more in limb  
 
        leads 
 
• new onset Left Bundle Branch Block  (LBBB) 
 
• evidence of true posterior infarct. 
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Absolute contraindications to lysis include: 
  
• risk of bleeding (recent trauma, major surgery or head injury within 6 weeks)  
 
• gastrointestinal haemorrhage or proven peptic ulcer disease in the  
 
              past 3 months 
  
• bleeding diathesis or chronic liver disease complicated with portal  
 
               hypertension 
 
• cerebrovascular accident (residual disability) or transient ischemic attack in the  
 
               past 6 months 
 
• pregnancy 
 
• allergy to fibrinolytic ( streptokinase or anistreplase should not be  
 
               repeated if given in the previous 5 days to 12 months). 
 
Relative contraindications include: 
 
• hypertension (Systolic Blood Pressure > 180 mmHg or Diastolic Blood Pressure >  110  
 
        mmHG) in which case urgent blood pressure lowering is required before administering  
 
        fibrinolysis 
 
• non compressible arterial puncture or dental extraction in the  past 2 weeks 
 
•  prolonged Cardio Pulmonary Resuscitation (CPR) 
 
• diabetic proliferative retinopathy and any other serious disease carrying a high risk of  
 
                 bleeding.(43,44) 
 
 
Due to economic limitations, streptokinase is the fibrinolytic used in the public sector hospitals  
 
of Cape Town for treatment of STEMI’s. It needs to be reconstituted and given as an infusion. 
 
Alteplase, available at Victoria and New Somerset Hospitals, is reserved for use in those  
 
patients who had previously received streptokinase.   
20 
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The Door to Needle Time as a Quality of Care Marker: 
 
The AHA/ACC guidelines recommend a door to needle time of 30 minutes or less for  
 
administration of fibrinolytics in patients with STEMI.(43,43) Compliance with this time period is  
 
internationally accepted as a marker of quality of care.(45)  McNamara et al in their study of 
 
62470 STEMI patients that were thrombolysed showed lower in-hospital mortality in patients  
 
with shortened door to needle times.(12) 
 
Despite the proven advantages of early fibrinolysis, audits performed internationally show that  
 
most hospitals fail to achieve a door to needle time of 30 minutes or less in about half their 
 
 patients.(40, 46-51)  No South African data on the  EC administration of fibrinolytics for STEMI  
 
were found. 
 
 
There are various factors implicated in the delay in achieving optimal reperfusion times.  
 
Identifiable factors include:  
 
1. Pre-hospital Factors: 
 
• Patient delay in seeking medical attention and activation of EMS. 
 
• Pre-hospital transport delays. 
 
 
               2.   In-hospital Factors   
 
• Prolonged door to needle times are due to delays in identifying patients  
 
      with chest pain or those presenting with atypical symptoms, ineffective or  
 
      lack of triage systems in ECs, delays in obtaining a 12 lead ECG and  
 
      difficulty in ECG interpretation. 
 
• In cases identified with STEMI, delays in starting fibrinolytics timeously  
 
       contributed to prolonged door to  needle times.(38,50) 
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Pre-hospital Factors Delaying Thrombolysis: 
 
Patient delays can be attributed to the lack of awareness or knowledge about fibrinolytic  
 
therapy and the need for early intervention in those with AMI; patient denial of having an AMI  
 
or inability to contact medical care due to their medical condition, or having no access to  
 
telecommunications.(52,53) 
 
Pre-hospital transport delays can occur, secondary to limited resources such as availability of  
 
ambulances and staff. It is also influenced by the level of experience of the pre-hospital care  
 
giver and the availability of 12 lead ECG machines in the ambulances. 
 
 
In-hospital Factors Delaying Thrombolysis: 
  
The door to needle time is an important time sub-interval that can be influenced by in-hospital  
 
medical personnel and EC protocols. The door to needle time can be divided into the door to  
 
triage time, triage to ECG time and time from ECG acquisition to starting fibrinolytics. The sum  
 
of these times represents the door to needle time.  
 
Jehanger et al, in their review of 201 patients receiving fibrinolysis for STEMI found that a door  
 
to needle time of  less than 30 minutes was achieved in 54.7% of patients.(50) In the subgroup 
 
with a door to needle time of greater than 30 minutes (n 91), delays were attributed to the  
 
initial ECG showing subtle changes, requiring repeat ECG’s. In twelve percent of the time, there  
 
was a delay in decision making and starting of the fibrinolysis. Patients complicated with  
 
ventricular fibrillation that required resuscitation accounted for seven percent of delays.(50)  No  
 
reason could be found in one and a half percent of cases. 
 
Similar delays were identified in a small study done by Masurker et al in Mumbai (40). There are 
 
certain patient factors such as cardiac arrest and hypertension (blood pressure beyond 
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recommended guidelines) that require correction first, before commencing thrombolytics, 
 
hence causing an unavoidable prolongation in door to needle times.    
 
Magid et al investigated the effect the time of day, day of week and time to reperfusion had on  
 
door to needle times and correlated it with mortality. In the door to drug segment of the study  
 
67.9% (n -68439) patients received fibrinolytic therapy after hours. Door to needle times were  
 
statistically slightly longer during after hours (34.3 min) than regular working hours (33.2 min)  
 
{95% CI 0.7 –1.4, P< .001}.  
 
The absolute difference was 1 minute. They concluded that patient arrival time did not influence  
 
the fibrinolytic treatment time subintervals appreciably.(54)   
 
In determining mortality after adjusting for all patient co-variants, patients presenting after  
 
hours had higher in hospital mortality, but the difference was considered not statistically  
 
significant [OR 1.06; 95%CI,  0.98-1.15 P=0.13].(54) 
 
The AMI- Quebec study also retrospectively investigated the delays in reperfusion therapy for  
 
STEMI’s in 17 hospitals in Quebec, Canada. Forty nine percent of patients were thrombolysed 
 
 within 30 minutes of arrival. Patients presenting outside working hours had longer door to  
 
needle times. Median door to ECG times were twelve minutes for patients presenting during 
 
 normal working hours and thirteen minutes  for those presenting after hours. Fewer staff being 
  
present after hours was identified as a probable cause of this delay.(48)  
 
The time of presentation to hospital however did not seem to significantly affect the door to  
 
needle time when statistical analysis was undertaken. 
  
 
The AHA/ACC guidelines recommend a door to ECG time of ten minutes in all patients with 
 
chest pain/discomfort or symptoms suspicious of acute coronary syndromes(ACS). This also 
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included interpretation of the ECG.( 44,55-57)  Despite set recommendations, studies done 
 
internationally show that approximately a third of patients with ACS received ECGS within ten 
 
minutes.(58,59)     
 
Prolonged door to ECG times led to an increase risk of adverse clinical outcomes at 30 days in  
 
STEMI patients [OR 3.95 95%CI, 1.06 – 14.72, P =0.04].(56) Adverse outcomes were secondary to  
 
prolongation of the reperfusion time. The door to ECG time is a sub interval in the calculation of  
 
the door to reperfusion time. 
 
 
Various studies also investigated the influence that patient demographics had on door  
 
to needle times.(48,60-63) An increased age was associated with decreased odds of timely  
 
administration of fibrinolysis. Possible factors identified were atypical symptoms being more 
 
prevalent in the elderly. The elderly were also thought to be at increased risk of intracranial 
 
haemorrhage, which may have deterred doctors from administrating fibrinolysis initially. The 
 
average age of patients receiving fibrinolysis was 60.2 years with a male predominance.(48,60- 
 
63) There therefore needs to be a high index of suspicion for STEMI in elderly patients (greater  
 
than 60 years) presenting to ECs.  
 
 
Quality Improvement Strategies: 
 
Most studies and audits reviewed suggest an efficient, organised team based approach to  
 
reduce door to needle times.(38,46,48,54,64-67)  Development of institutional or provincial  
 
care pathways should be emphasised. This requires pre-hospital care providers, hospital  
 
administration, emergency centre staff and pharmacists to be part of an integrated team  
 
response. 
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    Prehospital Quality Improvement Strategies: 
 
    Patient factors described above need to be addressed by extensive public education and 
 
    improvement of infrastructure.(15,50) 
 
    The role of paramedics in the management of patients with possible ACS, is to take a goal  
 
    directed history; obtain a 12 lead ECG, complete a reperfusion checklist en-route to hospital,  
 
    and prioritise all of the above information during patient handover at the receiving  hospital.  
 
    In a US study, pre-hospital ECG acquisition led to a 36.1 minutes mean savings in the door to  
 
    needle time.(68) This could correlate into improved mortality and morbidity in STEMI  
 
    patients. 
 
    In the Western Cape, not all paramedics in the public sector are equipped with 12 lead ECG  
 
    machines.  
 
    Many pre-hospital staff attending to ACS’s has variable levels of training (Basic Life 
 
    Support to Advanced Life Support), making paramedic initiated ECG acquisition difficult. 
  
    Current handover practice in Western Cape Emergency Centres between pre-hospital staff 
 
    and hospital staff is mainly by verbal communication and an ambulance record sheet.  
 
    A DeMIST system introduced by METRO Emergency Medical Services recently aimed at more  
 
    efficient handover practices.(69) The DeMIST emphasises important patient demographics,  
 
    mechanism of injury or type of illness, vital signs and treatment given.(69,70) The DeMIST  
 
    system can be adapted to use during handover  of STEMI patients but requires training of  
 
    pre-hospital and in hospital staff.(70) 
 
 
    Advance notification by pre-hospital staff to the receiving hospital is also important in aiding 
 
    the EC staff in preparing for the STEMI patient. 
 
    Initiation of pre-hospital fibrinolysis should also be considered, although no protocol has been  
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    set up in the Western Cape. Pre-hospital fibrinolysis can decrease call to needle times and has  
 
    the potential to decrease morbidity and mortality in STEMI patients.(71,72) 
 
     
    In-hospital quality improvement strategies: 
 
    Recommendations for improving in-hospital care of patients arriving with ACS include the  
 
    establishment of efficient patient flow and  triaging systems, so that patients with chest pain  
 
    could be fast  tracked.(64) 
  
    The South African Triage Scale (SATS) is used in the Western Cape. It consists of triage  
 
    early warning indicators (vital signs) and a discriminator list. The discriminator list is the final  
 
    factor used to determine the triage colour and severity of the patient. Chest pain is 
 
    incorporated as a discriminatory factor, enabling the triage officer to ‘uptriage’ a patient even  
 
    if their vital signs are normal. This helps identify and prioritise patients with chest pain.(73,74)  
 
    Efficient triaging can thus lead to shorter door to needle times. 
 
   Organisational and administrational support also plays an important role in rapidly 
 
    investigating chest pain patients. Obtaining a door to ECG time of ten minutes should be 
 
    aimed for.(54) This rapidly identifies patients with STEMI’s enabling the clinician to timeously 
 
    work up the patient for a reperfusion strategy. 
 
 
    Good senior physician leadership, knowledge and managerial experience in the EC can help  
 
    expedite fibrinolysis in eligible patients. It has been shown that ECG interpretation and  
 
    decision to thrombolyse were more reliable in the more experienced doctors compared to  
 
    junior doctors.(75) Furthermore, computer generated ECG reports did not seem to reduce  
 
    errors in ECG interpretation.(76)  It is therefore important for a senior Emergency   
 
    Physician to oversee junior staff and provide advice on difficult management decisions and  
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    disposition of patients. A good professional relationship between EC doctors, cardiologists,       
 
    nursing staff and support personnel also aids in providing fibrinolysis timeously.    
 
    Establishing a specific chest pain team to co-ordinate fibrinolysis may be ideal.  
 
 
    There should be local standard protocols developed for EC doctors and nurses to follow for a 
 
    patient arriving with a STEMI. The AHA/ACC has developed an acute coronary syndrome   
 
    algorithm to aid in managing patients with ACS.(44) The algorithm could be incorporated 
 
    into local protocols. 
 
    Emphasis should also be placed on efficient management of STEMI patients arriving after 
 
    hours.(38) 
 
 
The type of service an EC of a hospital provides can be determined by analysing its quality of  
 
care markers. Efficient management of patients with AMI forms a critical segment of EC care  
 
and early fibrinolytic therapy does influence patient morbidity and mortality.(35) Quality of care  
 
markers such as timeliness of obtaining an ECG, early administration of drugs such as aspirin,  
 
timely fibrinolytic therapy and efficient disposition of STEMI patients can be used to determine  
 
emergency centre performance in the management of patients with AMI.(46,77,78) The  
 
American College of Cardiology, Door to Balloon Alliance and the American Heart Association’s  
 
Mission: Lifeline programs initiated in the US aims at improving health care systems for STEMI  
 
patients requiring reperfusion.(79) Achieving the target door to needle time  of 30 minutes  or   
 
less is an acceptable and appropriate benchmark  for providing quality care for STEMI patients in  
 
Western Cape hospitals.    
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Abstract 
 
Objectives: 
 
To determine the current door to needle time for the administration of fibrinolytics for Acute  
 
Myocardial Infarction (AMI) in Emergency Centres (EC) at three hospitals in Cape Town, and to  
 
compare it to the current American Heart Association/American College of Cardiology  
 
(AHA/ACC) recommendation of 30 minutes. 
 
Methods: 
 
 A retrospective audit of all patients receiving thrombolytics for AMI in the ECs of three Cape  
 
Town hospitals was performed. Case notes from January 2008 to July 2010 were reviewed. The  
 
total door to needle time was calculated. In addition, patient demographics and presentation,  
 
physician qualification, clinical symptomology, infarct location  and reasons for delays in  
 
thromobolytic administration were also analysed. 
 
Results: 
 
A total of 372 patients with acute ST elevation myocardial infarction (STEMI) were identified.  
 
One hundred and sixty one patients were eligible for this study. The median door to needle time  
 
achieved was 54 minutes ( Range 13 -553 min). A door to needle time of 30 minutes or less was  
 
achieved in 33 patients (20.5%). More than half of the patients (51.3%) arrived by ambulance.  
 
Thirty four percent of patients had a pre-hospital 12 lead ECG. The majority (88.8%) had typical  
 
symptoms of myocardial infarction. Medical Officers administered thrombolytics to 44.7% 
 
 of the cases thrombolysed. The predominant infarct location on ECG was inferior (55.9%). 
 
Conclusion: 
 
A significant number of patients were not thrombolysed within 30 minutes of presentation.  The  
 
lack of senior doctors, difficulty interpreting ECGs, atypical presentations and EC system delays   
 
prolonged the door to needle time in this study.                                                                                  39                                                     
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INTRODUCTION 
 
Ischaemic Heart Disease (IHD) is a major cause of mortality and morbidity worldwide, especially  
 
in industrialised countries.[1]  In the Western Cape, IHD has been reported as the leading cause  
 
of mortality in the cardiovascular category in the year 2000 and has consistently appeared in the  
 
top five causes of mortality since.[2] In keeping with international studies mortality from IHD  
 
was higher in males than females.[3] 
 
While primary prevention of IHD is considered the ideal, mortality and morbidity in patients  
 
presenting with Acute Myocardial Infarction (AMI) can be reduced with early interventions such  
 
as fibrinolysis or percutaneous coronary intervention (PCI).[4] Multiple studies have shown that  
 
early PCI is more advantageous in reducing mortality  from re-infarction and the need for  a  
 
coronary artery bypass graft (CABG) than fibrinolytic drug therapy.[5-7] In the Western Cape PCI  
 
is limited to two tertiary hospitals, making fibrinolytic drug therapy the more accessible form of  
 
treatment for ST elevation myocardial infarction (STEMI)  patients. 
 
Early administration of fibrinolytic therapy has shown to improve patient outcomes in terms of  
 
limiting infarct size,  thus  preserving  left ventricular function.[8,9]  This is achieved by re- 
 
establishing the patency of the occluded coronary vessel.[8-10] Maximal benefit from  
 
fibrinolysis is seen when the fibrinolytic is given within the first hour of symptom onset.[11,12]  
 
 Delaying  fibrinolytic therapy by one hour increases the hazard ratio of death by 20%, (95% CI 7  
 
– 88), and a delay of 30 minutes or more can reduce the average life expectancy by one  
 
year.[13]  
 
Minimising the time delay between onset of symptoms to definitive treatment is integral in  
 
improving mortality and morbidity.  
 
 The period between the onset of symptoms to administration of fibrinolytic therapy can be 
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 divided into the following components: 
 
• Interval between onset of symptoms to seeking medical attention 
 
• Period taken to transport patient to definitive care 
 
• Interval between arrival at hospital to initiation of fibrinolytics (door to needle time) 
 
The first two components can be improved by public education and developing efficient  
 
pre-hospital systems. The door to needle time is the one in-hospital factor that can be  
 
addressed by medical practitioners. 
 
The American Heart Association /American College of Cardiology (AHA/ACC) guidelines  
 
recommend a door to needle time of 30 minutes or less for administration of fibrinolytics for  
 
STEMI patients.[14] Compliance with this time period is considered a marker of quality of  
 
care.[15]  
  
No current data could be found on the door to needle time in the Emergency Centres (EC) of  
 
public hospitals in Cape Town . The aim of this study is to determine the current door to needle  
 
time for fibrinolytic administration in patients with STEMI’s, determine patient demographics  
 
and assess factors that could influence the door to needle time. 
 
 
METHODS 
 
A retrospective audit was conducted of all patients who received thrombolytics for AMI in the  
 
ECs of 3 hospitals in Cape Town from January 2008 to July 2010. 
 
Inclusion criteria: 
 
• All adult patients with acute ST segment elevation, new onset Left Bundle Branch Block  
 
      (LBBB), or posterior infarct on electrocardiogram (ECG) meeting AHA/ACC criteria for  
 
       thrombolysis, who  received thrombolytics in the above ECs. 
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The following patients were excluded: 
 
• patients who received pre-hospital thrombolysis or those thrombolysed at other centres 
 
        before referral. 
 
• Patients receiving thrombolysis for conditions other than myocardial infarction. 
 
• Cases where patient files were missing from central records and cases with incomplete  
 
        data such that door to needle time could not be calculated. 
 
 
Data Collection 
 
 Patients with a diagnosis of acute coronary syndrome, acute myocardial infarction and ST  
 
elevation myocardial infarction were identified from the EC registry. Case notes were reviewed  
 
by a single observer. The required data were extracted onto a standardised data collection form.   
 
The quality of data collected was dependent on the availability and accuracy of the case notes.  
 
Incomplete documentation, illegible and ambiguous notes were identified.   
 
The following data were collated and analysed: 
 
• Patient demographics 
 
• Transport mode to hospital 
 
• Pre-hospital ECG acquisition , either by Emergency Medical Services (EMS) or  the  
 
primary care facility staff. 
 
• Time of day (working hours vs. after hours) patient arrived. Working hours was defined  
 
               as 08.00 to 17.00 and after hours between 17.00 and 08.00 the next day. No distinction  
 
               was made between weekdays or weekends as the EC’s had similar staffing and  
 
               dynamics on both weekdays and weekends. 
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The following time intervals were calculated: 
 
• Earliest time of presentation to hospital (taken from EMS records or admission chart) to  
 
time of triage. 
 
• Time from triage to ECG acquisition. 
 
• Time from ECG acquisition to actually commencing thrombolytics. 
 
This time interval included interpretation of ECG, obtaining consent for administration of  
 
thrombolytic, determining if any contraindications existed to the thrombolytic agent, obtaining  
 
intravenous access and preparing the thrombolytic for administration. 
 
The sum of the above time intervals constitutes the total door to needle time. 
 
All data were collected and transferred onto an Excel spreadsheet. Simple descriptive statistics  
 
were used to describe the  median time to triage, triage to ECG, ECG to fibrinolytic and total  
 
door to needle times.  
 
Subgroup analysis was performed for determining prevalence of STEMI’s fibrinolysed based on  
 
gender and age group; anatomical localization of myocardial infarction;  transport times and  
 
level of experience of treating  physician.  
 
The symptomology on presentation was also assessed. Typical symptoms were defined as an 
 
 acute onset of chest pain with radiation to the left arm, neck or jaw with associated autonomic 
 
 symptoms ( sweating, nausea or vomiting). 
 
 Statistical analysis was undertaken using Microsoft Excel (Microsoft, Richmond, Va), EpiCalc  
 
2000 (Brixton Books, London, UK) and STATA (Stata Corp, College St, Tx).  
 
 
RESULTS 
 
From the EC registries of the 3 hospitals under study a total of 372 patients with STEMI were 
 
 identified. The final number included in the study was 161.  
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The consort diagram is shown as Figure 1. 
 
Table 1 lists the demographic variables.  
 
DEMOGRAPHIC VARIABLE MEDIAN 
(RANGE) 
N(%)/  
95% CI  
Median age(yrs) 54 (31-84)  
Sex    
      Male    66.5 (58.5, 73.6)  
      Female   33.5 (26.4, 41.4) 
Mode of arrival    
      Ambulance   51.2 (43.2, 59.2) 
      Walk –in  48.8 (40.8, 56.7) 
Time of arrival   
       Working hours  52.2 (39.9, 55.8) 
        After hours  47.8 (44.2, 60.1) 
Prehospital ECG  33.9 (26.8, 41.9) 
Median pain to arrival time(min) 192.5 (10-765)  
Symptomology    
         Typical   88.8 (82.7, 93.1) 
         Atypical   11.2 (6.9, 17.3) 
 
TABLE 1: DEMOGRAPHIC VARIABLES   
 
 
The majority of patients, 39.8% (95% CI 32.1, 47.4), thrombolysed were in 45 to 54 year age  
 
group, with the next highest in 55 to 64 year age group. 
  
A door to needle time of 30 minutes or less was achieved in 33 (20.5%) patients. Table 2 shows  
 
the door to needle time of the entire study.  
 
 
 
 
 
 
 
 
 
TABLE 2:  DOOR TO NEEDLE TIME IN MINUTES 
 
The median door to needle time was 54 minutes (Range 13 - 553). Table 3 depicts the median  
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%/ N -161 
WITHIN 30 MIN 20.5 (33) 
31 -60 MIN 37.9 (61) 
61 -90 MIN 26.7 (43) 
> 90 MIN 14.9 (24) 
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time achieved for each of the intervals studied. 
 
TIME INTERVAL MEDIAN TIME (RANGE) 
MINUTES 
DOOR TO TRIAGE 6 ( 0 -157) 
TRIAGE TO ECG 2 (0 -245) 
DOOR TO ECG 13 (1-402) 
ECG TO FIBRINOLYTIC 38 (4 -262) 
DOOR TO NEEDLE                                                        54 (13 -553) 
 
TABLE 3: MEDIAN TIME ACHIEVED FOR EACH INTERVAL IN MINUTES  
 
Most of the patients, (44.7% {36.9, 52.7}), were seen and given fibrinolysis by medical officers,  
 
with 34.8 % (27.5, 42.7)  treated by emergency medicine registrars. The rest of the patients  
 
were seen and treated by interns (4.4% {1.9, 9.1}), junior community service doctors (14.9% 
 
 {9.8, 21.6}), and emergency physicians (1.2% {6.2, 14.9}). 
 
The predominant infarct location on ECG was inferior (55.9% {47.9, 63.6}) followed by  
 
anterior (38.5% {31.0, 46.5}).  A door to ECG time of less than ten minutes was achieved in  
 
41.2% of patients. 
 
The influence of mode of arrival, time of arrival, symptomology, pre-hospital ECG and level of  
 
experience of treating doctor on the door to needle time was assessed and are listed in Table 4.  
 
 
VARIABLE MEDIAN DOOR TO 
NEEDLE TIME (RANGE) 
MINUTES 
MODE OF ARRIVAL:  
                    AMBULANCE 53 (10-553) 
                    WALK IN 50 (10-270) 
TIME OF ARRIVAL:  
                    WORKING HOURS 53 (15-553) 
                    AFTER HOURS 54.5 (13-457) 
SYMPTOMOLOGY:  
                    TYPICAL 53 (13-245) 
                    ATYPICAL 65 (17-553) 
PREHOSPITAL ECG:  
                    YES 50 (15-553) 
                    NO 55 (13-270) 
LEVEL OF EXPERIENCE OF DOCTOR:                           
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                    MEDICAL OFFICER                                                           50 (17-553)                            
                    EMERGENCY MEDICINE REGISTRAR                            55 (15-195)                              
 
TABLE 4: COMPARISON OF MEDIAN DOOR TO NEEDLE TIMES 
                                                             
The reasons for delays in fibrinolytic therapy were documented by the attending doctor in 70 of  
 
the 161 cases (43.5%). 
 
Delays in initiating fibrinolytic therapy were due to: 
 
• The attending doctor seeking  advice from the senior doctor in the EC or the Internal  
 
        Medicine registrar before commencing fibrinolysis. The reason for consulting the senior  
 
        was not documented.(28.6%) 
 
• Difficulty in interpreting the ECG.(18.6%) 
 
• Patients presenting with atypical symptoms, hence delaying the diagnosis of  
 
               AMl.(12.9%) 
 
• Patients going into cardiac arrest and requiring cardiopulmonary resuscitation (CPR)  
 
       before thrombolytic therapy could be commenced.(11.4%) 
 
• Patients presenting with hypertension (systolic blood pressure greater than 180 mmHg) 
 
        which is a relative contraindication to fibrinolysis. Blood pressure control was needed  
 
        before administration of fibrinolytics.(7.1%) 
 
• Patients presenting during change of shifts for nurses or doctors were not attended  to  
 
timeously.(7.1%) 
 
• Delays in obtaining a chest X Ray.(4.3%) 
 
• Fibrinolytic agent not available in the EC. The nurse had to fetch  it from the  
 
        pharmacy.(4.3%) 
 
• Waiting for results of cardiac enzymes, non availability of intensive care beds and  
 
        equipment (infusion pump) failure accounted for the remainder of the delays.(5.7%) 
    46 
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DISCUSSION 
 
Minimising the time between the onset of an AMI to initiation of a reperfusion strategy is  
 
important for improving prognosis and survival.[11,12]  In this study less than a third of patients  
 
with STEMI received thrombolytics within the prescribed time interval of 30 minutes. The  
 
median door to needle time of 54 minutes was higher than that of North American and  
 
European hospitals which recorded median door to needle times of less than 45 minutes.[16-19]  
 
It was comparable to studies done in the Middle East, Pakistan and India, and one study done  
 
by Zed et al in Vancouver.[20-23] However it should be noted that in some of the above studies  
 
thrombolysis was given in the intensive care unit (ICU) and not in the EC thereby prolonging  
 
door to needle times. 
 
 The number of patients thrombolysed within 30 minutes was lower than other contemporary 
 
studies, although some of these studies had smaller sample sizes.[16,17,20-23] 
 
The key modifiable factors in this study contributing to prolonged door to needle times were the  
 
need for senior review or advice on ECG interpretation. This contributed to almost half of the  
 
documented delays in thrombolysis. This delay in diagnosis or ECG interpretation has been  
 
identified in other studies as a contributory factor to prolonged door to needle times.[20,21]  
 
In our setting physician experience may also be a contributory factor. Medical Officers working  
 
in Cape Town public sector hospitals have variable levels of experience and training. Emergency  
 
Medicine is also a relatively new speciality in South Africa, with emergency medicine registrars  
 
at different points in their training.  Although Medical Officers had shorter median door to  
 
needle times than Emergency Medicine (EM) registrars, they had a wider range compared to  
 
EM registrars. It has been shown that ECG interpretation and the decision to thrombolyse were  
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more reliable in more experienced doctors compared to junior doctors.(24) Other reasons for  
 
seeking senior advice could not be reliably identified from the case notes. 
 
Patients presenting with atypical symptoms or with undifferentiated chest pain require an ECG  
 
to diagnose a STEMI. A door to ECG time of less than 10 minutes has been recommended by the  
 
AHA/ACC for all patients with chest pain or symptoms suggestive of ACS.[14] It has been  
 
shown that a prolonged door to ECG time leads to an increased risk of adverse clinical outcomes  
 
in patients with a STEMI.[25] Our  study gave a median door to ECG time of 13 minutes  
 
(Range 1 -402 min), with less than 50% of patients having an ECG within 10 minutes. 
 
The three hospitals studied have busy EC’s often burdened with overcrowding. Overcrowding  
 
can prolong the door to triage sub interval of the door to needle time. The Western Cape  
 
employs the South African Triage Scale which has been validated in community health centres  
 
and hospitals.[26] It consists of 2 parts. A triage early warning score which involves taking the 
 
patients vitals, assessing the patients level of consciousness, mobility and evidence of trauma.  
 
The second component is a discriminator list which allows the “triager” to upgrade a patient to a  
 
higher colour category. Chest pain is part of this discriminator list and upgrades all chest pain  
 
patients to at least an orange category. All orange/red patients should be attended to  
 
immediately or within 10 minutes of presentation.[26] The median  door to triage time was  
 
6 minutes. The time from triage to first physician contact was not measured in this study due to  
 
the poor record keeping of this time in the patient records. 
 
 
The organisational ability and patient flow characteristics of a hospital also influences door to  
 
needle times. Multiple factors that hindered patient flow were identified in this review. Delays   
 
in obtaining x rays, patients arriving during nurse and doctor handovers not being attended to  
 
timeously,  and prolonged door to ECG times all suggest shortcomings in patient flow pathways.     
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 The ECG to commencement of fibrinolytic time interval constituted the longest delay in the  
 
door to needle time. Delays identified in this interval are attributed to patient factors and  
 
physician factors. A proportion of patients went into cardiac arrest and required  
 
cardiopulmonary resuscitation. Others presented with hypertension, which required blood  
 
pressure lowering before commencing lysis.   
 
 
Pre-hospital factors prolonging door to needle times included patient demographics, pre- 
 
hospital transport delays and time of presentation to hospital.  
 
The AMI QUEBEC STUDY  investigated some of these factors. The study found that older  
 
patients had a decreased likelihood of getting timeous reperfusion therapy.[16] Possible  
 
reasons for this were that elderly patients had more atypical symptoms and also had increased 
  
risk of complications from fibrinolysis.[27,28] Patients presenting after hours  had longer door  
 
to needle times, probably due to  fewer staff being available after hours.[16] In another study  
 
the time to fibrinolyisis did not differ much by patient arrival time.[29] 
 
  
Patient factors such as denial of symptoms and delays in activating EMS also contribute to  
 
delayed fibrinolysis.[30] 
 
Pre-hospital transport delays secondary to resource limitations, the distance to hospital  
 
with reperfusion capability and  traffic delays are other contributory factors to prolonged times  
 
to fibrinolysis.[30,31]  
 
 
Although this study suggested that shorter median door to needle times were achieved in  
 
patients who arrived with their own transport, presented during working hours, had typical  
 
symptoms of AMI and in those that had a pre-hospital ECG, the sample size was small and it did  
 
not have the power to draw definite conclusions. 
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Most of the quality improvement studies suggest a team based approach to improving the time  
 
to reperfusion therapy for MI patients.[16,17,31] 
 
In our setting quality improvement audits need to focus on in-hospital and pre-hospital factors. 
 
 Most of the in-hospital reasons for delays in door to needle times identified in our study, could  
 
be improved through efficient triaging, early ECG acquisition for at risk patients, EC physician  
 
training , the presence of a senior doctor/physician  on the floor or being readily available  
 
telephonically, knowing your population profile and having a low threshold for investigating  
 
those with atypical symptoms.  
 
Other in hospital organisational strategies include close co-operation between hospital  
 
administration, emergency centre staff and auxiliary services to enhance patient flow, 
   
interpretation of the ECG by the most competent physician  in the EC. 
 
The ready availability of fibrinolytic stock in the EC, and r pid nurse driven administration  
 
of fibrinolytics once diagnosis has been made should be encouraged. 
 
 Keeping a provincial registry of all AMI presentations will aid in data analysis and protocol  
 
development. 
 
 
 Pre-hospital quality improvement in our setting should include education of the public to  
 
recognise signs and symptoms of AMI,  early activation of emergency services or accessing the  
 
nearest health facility. 
 
An integrated local EMS chest pain protocol supporting rapid diagnosis and pre-hospital ECG  
 
acquisition should be developed. 
 
 As earlier quality improvement audits done internationally have shown significant decreases in  
 
door to needle times, similar audits need to be done in Cape Town hospitals to improve door to  
 
needle time and hence reduce mortality and morbidity from STEMI.[17] Development of a  
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standardised protocol and checklist for thrombolysis would be beneficial in this regard. 
 
 
LIMITATIONS: 
  
This was a retrospective chart review and hence relied on the accuracy of data recorded.  
 
 A significant proportion of patient files (24.5%) could not be located from the central records of  
 
the hospitals under study.  Furthermore 15% of the files located had incomplete documentation  
 
or missing notes and could not be included in this study. Times recorded are dependent on the  
 
attending doctor or nurse. Fewer than 50% of the files had a reason for delay noted. These could  
 
have influenced the accuracy of our findings. 
 
 
 
CONCLUSION 
 
Only 20.5% (95% CI 14.71, 27.72) of patients with STEMI met the AHA/ACC guideline of receiving 
 
fibrinolytics within a 30 minute door to needle time. This is below international standards of  
 
greater than 40%.[22,23] 
 
There are multiple factors contributing to a prolonged door to needle time and need to be  
 
addressed by creating an efficient, team based approach to managing these patients. A repeat  
 
audit is needed once hospital systems are changed to determine if there is an improvement in  
 
the door to needle time. 
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APPENDIX  A 
 
DATA COLLECTION SHEET 
 
Patient Number:  _________________________ 
DEMOGRAPHICS: 
 Age: _____            Sex: ______             
 
AMBULANCE:  Y / N      
FORWARD ALERT BY PREHOSPITAL STAFF:  Y/N                 PREHOSPITAL ECG:  Y/N 
 
LEVEL OF EXPERIENCE OF TREATING PHYSICIAN:  INTERN, CSO, MO, REGISTRAR, CONSULTANT 
 
CLINICAL:     
 Time of Onset of Pain:  ________  Time of Day:  W/H, A/H 
 Anatomical localization: _________ 
 Typical Symptoms        Y / N 
 If no describe:  _________________________________ 
 
 
 DURATION COMMENT 
 TIME OF ARRIVAL   
TIME FROM ARRIVAL TO 
TRIAGE 
 
  
TIME FROM TRIAGE TO ECG               
TIME FROM ECG TO ACTUAL 
ADMINISTRATION OF 
FIBRINOLYTIC 
  
TOTAL DOOR TO NEEDLE 
TIME 
  
 
KEY: Y – YES 
           N – NO  
           CSO – COMMUNITY  SERVICE OFFICER 
           MO – MEDICAL OFFICER 
           W/H – WORKING HOURS ( 08:00 – 17:00) 
           A/H – AFTER HOURS ( 17:01 – 07:59) 
COMMENT: IDENTIFY DELAY IN DOOR TO NEEDLE TIME IF ANY 
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APPENDIX B 
 
EMERGENCY MEDICINE JOURNAL INSTRUCTION TO AUTHORS 
 
Original articles 
 
For full length accounts of original research, often shorter articles are better. Additional  
 
information may be placed on the web site as a data supplement. 
 
Word count: up to 3000 words.  
 
Illustrations and tables: up to 6. 
 
References:25. 
 
Peer review: all papers are reviewed by at least one reviewer. 
 
If there is uncertainty about acceptance after review, papers are reviewed by the editors. 
 
All material submitted is assumed to be submitted exclusively to the journal unless the contrary  
 
is stated. Submissions may be returned to the author for amendment if presented in the  
 
incorrect format.  
 
The title page must contain the following information: 
 
1. The title. 
 
2. The name, postal address, e--mail, telephone and fax numbers of the corresponding author. 
 
3. The full names, institutions, city and country of all co---authors. 
 
4. Up to five keywords or phrases suitable for use in an index (it is recommended to use MeSH 
 
terms). 
 
5. Word count --- excluding title page, abstract, references, figures and tables. 
 
The manuscript format must be presented in the following order: 
 
1. Title page 
                                                                                                                                                                                    
2. Abstract (or summary for case reports) 
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3. Main text (tables should be in the same format as your article and embedded into the  
 
   document where the table should be cited; images must be uploaded as separate files) 
 
4. Acknowledgments, Competing interests, Funding 
 
5. Copyright licence statement 
 
6. References 
 
7. Appendices 
 
Do not use the automatic formatting features of your word processor such as endnotes,  
 
footnotes, headers, footers, boxes etc. 
 
Provide appropriate headings and subheadings as in the journal. 
 
We use the following hierarchy: BOLD CAPS, bold lower case, Plain Text, Italics. Cite  
 
illustrations in numerical order (fig 1, fig 2 etc) as they are first mentioned in the text. Tables  
 
should be in the same format as your article and embedded into the document where the table  
 
should be cited.  
 
Images must  not be embedded in the text file but submitted as individual files. 
 
Statistics: Statistical analyses must explain the methods used. 
 
Style: Abbreviations and symbols must be standard and SI units used throughout except for  
 
blood pressure values which are reported in mm Hg. Acronyms should be used sparingly and  
 
fully explained when first used. 
 
Figures/illustrations: Black and white images should be saved and supplied as GIF, TIFF, EPS  
 
or JPEG files, at a minimum resolution of 300 dpi and an image size of 9 cm across for single  
 
column format and 18.5 cm for double column format. Colour images should be saved and  
 
supplied as GIF, TIFF, EPS or JPEG files, to a minimum resolution of 600 dpi at an image size of 
 
9 cm across for single column format and 18.5 cm for double column format. Images should be  
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mentioned in the text and figure legends should be listed at the end of the manuscript. During 
 
submission, when you upload the figure files please label them as Figure 1, Figure 2, etc. 
 
The file label will not appear in the pdf but the order in which the figures uploaded should be 
 
sufficient to link them to the correct figure legend for identification.  
 
Histograms should be presented in a simple, two---dimensional format, with no background  
 
grid.  
 
Tables: Tables should be submitted in the same format as your article and embedded into the 
 
document where the table should be cited. Tables should be self---explanatory and the data  
 
they contain must not be duplicated in the text or figures. 
 
 
References: Authors are responsible for the accuracy of references cited: these should be  
 
checked against the original  documents  before the paper is submitted. It is vital that the  
 
references are styled correctly so that they may be hyperlinked.  
 
In the text: References must be numbered sequentially as they appear in the text. References  
 
cited in figures or tables (or in their legends and footnotes) should be numbered according to  
 
the place in the text where that table or figure is first cited. 
 
Reference numbers in the text must be given in square brackets immediately after punctuation  
 
(with no word spacing) --- for example, [6] not [6]. Where more than one reference is cited,  
 
separate by a comma --- for example, [1, 4, 39]. For sequences of consecutive numbers, give the  
 
first and last number of the sequence separated by a hyphen --- for example, [22---25].  
 
References provided in this format are translated during the production process to superscript  
 
type, which act as hyperlinks from the text to the quoted references in electronic forms of the  
 
article. In the reference list: References must be double spaced (numbered consecutively in the  
 
order in which they are mentioned in the text) in the [slightly modified] Vancouver style.  
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Only papers  published or in press should be included in the reference list. (Personal  
 
communications or unpublished data must be cited in parentheses in the text with the  name(s)  
 
of the source(s) and the year. Authors should get permission from the source to cite  
 
unpublished data.) Punctuation of references must follow the [slightly modified] Vancouver  
 
style: 12 Surname AB, Surname CD. Article title. Journal abbreviation. Year;Vol:Start page---End  
 
page. Use one space only between words up to the year and then no spaces. The journal title  
 
should be in italic and abbreviated according to the style of Medline. If the journal is not listed in  
 
Medline then it should be written out in full. 
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Emergency Medicine 
Dear Dr Maharaj 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 4066338 • Facsimile [021] 4066411 
e-mail: sumayah.ariefdien@uct.ac.za 
PROJECT TITLE: A MULTI CENTRE REVIEW OF DOOR TO NEEDLE TIME FOR 
ADMINISTRATION OF FIBRINOLYTICS IN ACUTE MYOCARDIAL INFARCTION IN 
EMERGENCY CENTRES IN THE WESTERN CAPE METROPOLE 
Thank you for submitting your study to the Research Ethics Committee for review 
It is a pleasure to inform you that the Ethics Committee has formally approved the above-mentioned study. 
Approval is granted for one year till the 30th December 2010. 
Please submit an arulUal progress report if the research continues beyond the expiry date. Please submit a brief 
summary of findings if you complete the study within the approval period so that we can close our file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN P? CHAIRPERSON. HSF HUMAN ETHICS 
Federal Wide Assurance Number: FWA00001637. 
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